Showing results (321-330 of 369) with videos related to
Sort By:
Pageof 37
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|January 28, 2026
Real-world outcomes of stage III NSCLCs managed by surgery or definitive radiation therapy in the era of immunotherapyEtienne Abdelnour-Berchtold, Louis-Emmanuel Chriqui, Laetitia Zermatten, et al.European Journal of Cancer (Oxford, England : 1990)|September 18, 2021
Patient-reported outcomes for monitoring symptomatic toxicities in cancer patients treated with immune-checkpoint inhibitors: A Delphi studyAndré Manuel Da Silva Lopes, Sara Colomer-Lahiguera, Nuria Mederos Alfonso, et al.Revue Medicale Suisse|December 11, 2025
[Involving Patient Partners: Platforms and Strategies in French-Speaking Switzerland]Hélène Chanvrier, Alfredo Addeo, Cindy Allenbach, et al.Vaccines|August 26, 2023
SARS-CoV-2 m-RNA Vaccine Response in Immunocompromised Patients: A Monocentric Study Comparing Cancer, People Living with HIV, Hematopoietic Stem Cell Transplant Patients and Lung Transplant RecipientsNatacha Bordry, Anne-Claire Mamez, Chiara Fedeli, et al.Eclinicalmedicine|February 21, 2024
Impact on costs and outcomes of multi-gene panel testing for advanced solid malignancies: a cost-consequence analysis using linked administrative dataAlberto Hernando-Calvo, Paul Nguyen, Philippe L Bedard, et al.Lung Cancer (Amsterdam, Netherlands)|June 6, 2022
A prognostic score for patients with malignant pleural mesothelioma (MPM) receiving second-line immunotherapy or chemotherapy in the ETOP 9-15 PROMISE-meso phase III trialGiuseppe Luigi Banna, Alfredo Addeo, Panagiota Zygoura, et al.Iscience|January 3, 2022
Humoral and cellular immunogenicity two months after SARS-CoV-2 messenger RNA vaccines in patients with cancerNatacha Bordry, Alfredo Addeo, Cyril Jaksic, et al.Acta Oncologica (Stockholm, Sweden)|August 9, 2020
Impact of performance status on non-small-cell lung cancer patients with a PD-L1 tumour proportion score ≥50% treated with front-line pembrolizumabAlex Friedlaender, Giulio Metro, Diego Signorelli, et al.Journal of Thoracic Disease|February 8, 2020
Outcomes from salvage chemotherapy or pembrolizumab beyond progression with or without local ablative therapies for advanced non-small cell lung cancers with PD-L1 ≥50% who progress on first-line immunotherapy: real-world data from a European cohortGiulio Metro, Alfredo Addeo, Diego Signorelli, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|September 29, 2020
Efficacy of Pembrolizumab Monotherapy in Patients With or Without Brain Metastases From Advanced Non-Small Cell Lung Cancer With a PD-L1 Expression ≥50%Giulio Metro, Giuseppe Luigi Banna, Diego Signorelli, et al.Pageof 37